Mammoth Bio inks Crispr-based collaboration with Regeneron

25 April 2024
mammoth_big

Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a deal with privately held Mammoth Biosciences to research, develop and commercialize Crispr-based gene-editing therapies targeting multiple diseases.

The collaboration will expand Regeneron’s genetic medicines presence with more gene editing programs, and is designed to combine Mammoth’s platform with Regeneron’s effort to develop adeno-associated viral vectors (AAVs) that use antibody-based targeting to enhance delivery of genetic medicine payloads to specific tissues and cell types.

Financial terms of the accord

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology